Guidelines for Rational Clinical Use of Fentanyl Transdermal Patch

References

• World Health Organization. WHO guidelines for the pharmacological and radiotherapeutic management of cancer pain in adults and adolescents. World Health Organization; 2018. Available from: https://apps.who.int/iris/handle/10665/279700. Accessed January 19, 2024.
   Google Scholar
• World Health Organization. Model list of essential medicines; 2019. Available from: https://list.essentialmeds.org/. Accessed January 19, 2024.
   Google Scholar
• Deng G. Integrative medicine therapies for pain management in cancer patients. Cancer J. 2019;25(5):343–348. doi:10.1097/PPO.0000000000000399
   PubMed Web of Science ®Google Scholar
• Davis MP. Fentanyl for breakthrough pain: a systematic review. Expert Rev Neurother. 2011;11(8):1197–1216. doi:10.1586/ern.11.63
   PubMed Web of Science ®Google Scholar
• Yang M, Z. X, M. M, et al. CSCO guidelines for metastatic colorectal cancer: personalized medicine in clinical practice. Cancer Biol Med. 2023;20:640–645. doi:10.20892/j.issn.2095-3941.2023.0211
   PubMed Web of Science ®Google Scholar
• Hair PI, Keating GM, McKeage K. Transdermal matrix fentanyl membrane patch (matrifen): in severe cancer-related chronic pain. Drugs. 2008;68:2001–2009. doi:10.2165/00003495-200868140-00005
   PubMed Web of Science ®Google Scholar
• Yu SY. New dosage form of fentanyl. Clin J Pract Hosp. 2006;3:94–95.
   Google Scholar
• Pathan H, Williams J. Basic opioid pharmacology: an update. Br J Pain. 2012;6:11–16. doi:10.1177/2049463712438493
   PubMedGoogle Scholar
• Zhuang Y, Wang Y, He B, et al. Molecular recognition of morphine and fentanyl by the human mu-opioid receptor. Cell. 2022;185:4361–75 e19. doi:10.1016/j.cell.2022.09.041
   PubMed Web of Science ®Google Scholar
• Thompson JP, Bower S, Liddle AM, Rowbotham DJ. Perioperative pharmacokinetics of transdermal fentanyl in elderly and young adult patients. Br J Anaesth. 1998;81(2):152–154. doi:10.1093/bja/81.2.152
   PubMed Web of Science ®Google Scholar
• Collins JJ, Dunkel IJ, Gupta SK. Transdermal fentanyl in children with cancer pain: feasibility, tolerability, and pharmacokinetic correlates. J Pediatr. 1999;134(3):319–323. doi:10.1016/S0022-3476(99)70457-9
   PubMed Web of Science ®Google Scholar
• Grond S, Radbruch L, Lehmann KA. Clinical pharmacokinetics of transdermal opioids: focus on transdermal fentanyl. Clin Pharmacokinet. 2000;38:59–89. doi:10.2165/00003088-200038010-00004
   PubMed Web of Science ®Google Scholar
• Pettifer GR, Hosgood G. The effect of inhalant anesthetic and body temperature on peri-anesthetic serum concentrations of transdermally administered fentanyl in dogs. Vet Anaesth Analg. 2004;31(2):109–120. doi:10.1111/j.1467-2987.2004.00158.x
   PubMed Web of Science ®Google Scholar
• Kyles AE, Papich M, Hardie EM. Disposition of transdermally administered fentanyl in dogs. Am J Vet Res. 1996;57:715–719.
   PubMed Web of Science ®Google Scholar
• Egger CM, Glerum LE, Allen SW, Haag M. Plasma fentanyl concentrations in awake cats and cats undergoing anesthesia and ovariohysterectomy using transdermal administration. Vet Anaesth Analg. 2003;30(4):229–236. doi:10.1046/j.1467-2995.2003.00109.x
   PubMed Web of Science ®Google Scholar
• Mather LE. Clinical pharmacokinetics of fentanyl and its newer derivatives. Clin Pharmacokinet. 1983;8(5):422–446. doi:10.2165/00003088-198308050-00004
   PubMed Web of Science ®Google Scholar
• Hess R, Herz A, Friedel K. Pharmacokinetics of fentanyl in rabbits in view of the importance for limiting the effect. J Pharmacol Exp Ther. 1971;179:474–484.
   PubMed Web of Science ®Google Scholar
• Camu F, Vanlersberghe C. Pharmacology of systemic analgesics. Best Pract Res Clin Anaesthesiol. 2002;16(4):475–488. doi:10.1053/bean.2002.0262
   PubMedGoogle Scholar
• FDA. Duragesic: fentanyl transdermal system[EB/OL]; 2005. Available from: http://www.fda.gov/cder/foi/label/2005/19813s039lb.lpdf. Accessed January 19, 2024.
   Google Scholar
• Moore RA, Hand CW, McQuay HJ. Opiate metabolism and excretion. Bailliere’s Clin Anaesthesiol. 1987;1:829. doi:10.1016/S0950-3501(87)80038-7
   Google Scholar
• Fallon M, Giusti R, Aielli F, et al. Management of cancer pain in adult patients: ESMO clinical practice guidelines. Ann Oncol. 2018;29:iv166–iv91. doi:10.1093/annonc/mdy152
   PubMed Web of Science ®Google Scholar
• 2021 NCCN Adult Cancer Pain. Version 1.2021, 02/26/2021 © 2021 National Comprehensive Cancer Network® (NCCN®). NCCN Clinical Practice Guidelines in Oncology-Adult Cancer Pain. (2021 Version2) [DB/OL]. Available from: https://www.nccn.org/professionals/physician_gls/pdf/pain.pdf. Accessed January 19, 2024.
   Google Scholar
• Mercadante S. Options for treating pain in cancer patients with dysphagia. Drugs. 2017;77(6):629–635. doi:10.1007/s40265-017-0710-8
   PubMed Web of Science ®Google Scholar
• Xing S-Z, Zhang Y. Efficacy and safety of transdermal fentanyl for the treatment of oral mucositis pain caused by chemoradiotherapy in patients with esophageal squamous cell carcinoma. Support Care Cancer. 2015;23(3):753–759. doi:10.1007/s00520-014-2419-5
   PubMed Web of Science ®Google Scholar
• Guo S-P, Wu S-G, Zhou J, et al. Transdermal fentanyl for pain due to chemoradiotherapy-induced oral mucositis in nasopharyngeal cancer patients: evaluating efficacy, safety, and improvement in quality of life. Drug Des Devel Ther. 2014;8:497–503. doi:10.2147/DDDT.S60187
   PubMed Web of Science ®Google Scholar
• Wang YQ, Wang MJ, Qiu ZM. Application of transdermal fentanyl patch in cancer pain patients with renal insufficiency. J Pract Cancer. 2012;27:529–53v.
   Google Scholar
• Cheng Yi YS. The selective use of opioids in patients with liver and kidney dysfunction and cancer pain. Chin J Cancer. 2020;20:43–47.
   Google Scholar
• Yu SY, Qin SK, Xie GR. Expert consensus on the treatment of advanced cancer patients with intestinal obstruction. Chin J Cancer. 2007;29:637–640.
   Google Scholar
• Miyoshi T, Yamauchi H, Misumi N. [Efficacy and safety of transdermal fentanyl patches for opioid initiation in patients with gastrointestinal obstruction]. Gan Kagaku Ryoho. 2014;41(11):1401–1405. Japan.
   PubMedGoogle Scholar
• Yang Q, Xie D, Jiang ZM. Efficacy and adverse effects of transdermal fentanyl and sustained-release oral morphine in treating moderate-severe cancer pain in Chinese population: a systematic review and meta-analysis. J Exper Clin Cancer Res. 2010;29:67. doi:10.1186/1756-9966-29-67
   PubMed Web of Science ®Google Scholar
• Caraceni A, Hanks G, Kaasa S, et al. Use of opioid analgesics in the treatment of cancer pain: evidence-based recommendations from the EAPC. Lancet Oncol. 2012;13(2):e58–e68. doi:10.1016/S1470-2045(12)70040-2
   PubMed Web of Science ®Google Scholar
• Wang DD, Ma TT, Zhu HD, Peng CB. Transdermal fentanyl for cancer pain: trial sequential analysis of 3406 patients from 35 randomized controlled trials. J Cancer Res Ther. 2018;14:S14–S21. doi:10.4103/0973-1482.171368
   PubMed Web of Science ®Google Scholar
• Hadley G, Derry S, Moore RA, Wiffen PJ. Transdermal fentanyl for cancer pain. Cochrane Database Syst Rev. 2013;2013:CD010270. doi:10.1002/14651858.CD010270.pub2
   PubMedGoogle Scholar
• Liu JY, Xue J, Zhu T. Risk comparison of morphine sulfate sustained-release tablets, oxycodone hydrochloride sustained-release tablets and fentanyl transdermal patch in the treatment of cancer pain and constipation. China Pharm. 2015;16:316–318.
   Google Scholar
• Megens AA, Artois K, Vermeire J, Meert T, Awouters FH. Comparison of the analgesic and intestinal effects of fentanyl and morphine in rats. J Pain Symptom Manage. 1998;15:253–257. doi:10.1016/S0885-3924(97)00371-0
   PubMed Web of Science ®Google Scholar
• 2021 NCCN Adult Cancer Pain. Version 1.2021, 02/26/2021 © 2021 National Comprehensive Cancer Network® (NCCN®). NCCN Clinical Practice Guidelines in Oncology-Adult Cancer Pain. (2021 Version2) [DB/OL]. Available from: https://www.nccn.org/professionals/physician_gls/pdf/pain.pdf.PMID:34551388. Accessed January 19, 2024.
   Google Scholar
• Bemard B. Is transdermal fentanyl really better than sustained oral morphine. BMJ. 2015;322:1154–1158.
   Google Scholar
• Kang JH, Oh SY, Song S-Y, et al. The efficacy of low-dose transdermal fentanyl in opioid-naive cancer patients with moderate-to-severe pain. Korean J Intern Med. 2015;30(1):88–95. doi:10.3904/kjim.2015.30.1.88
   PubMed Web of Science ®Google Scholar
• Fu Q, Ran FM, Wang JZ. Clinical efficacy and safety of fentanyl transdermal patch in the treatment of moderate to severe cancer pain within 3 days. Cancer Progress. 2014;4:317.
   Google Scholar
• Yalcin S, Esin E. Neuropathic cancer pain: what we are dealing with? How to manage it. Oncot Ther. 2014;4:599–618. doi:10.2147/OTT.S60995
   Google Scholar
• Vuong C, Van Uum SH, O’Dell LE, Lutfy K, Friedman TC. The effects of opioids and opioid analogs on animal and human endocrine systems. Endocr Rev. 2010;31:98–132. doi:10.1210/er.2009-0009
   PubMed Web of Science ®Google Scholar
• Toru H. Molecular mechanisms of bone cancer pain. ClinCalc. 2014;24:1185–1191.
   Google Scholar
• El Mouedden M, Meert TF. The impact of the opioids fentanyl and morphine on nociception and bone destruction in a murine model of bone cancer pain. Pharmacol Biochem Behav. 2007;87:30–40. doi:10.1016/j.pbb.2007.03.017
   PubMed Web of Science ®Google Scholar
• Yu SY, Sun Y, Wu YL. Clinical efficacy analysis of transdermal fentanyl patch in the treatment of 4492 cases of cancer pain. Chin J Cancer. 2005;27:369–372.
   Google Scholar
• Cancer Clinical Chemotherapy Committee of China Anti Cancer Association. Cancer Support Therapy Committee of China Anti Cancer Association Chinese expert consensus on the prevention and treatment of nausea and vomiting related to tumor drug therapy (2019 edition). Chin J Med Front. 2019;11:16–26.
   Google Scholar
• Jee YS, Yoon HJ, Jang CH. Prophylactic antiemetic effects in gynecologic patients receiving fentanyl IV-patient controlled analgesia: comparison of combined treatment with ondansetron and dexamethasone with metoclopramide and dexamethasone. Korean J Anesthesiol. 2010;59:335–339. doi:10.4097/kjae.2010.59.5.335
   PubMedGoogle Scholar
• Nelson AD, Camilleri M. Opioid induced constipation: advances and clinical guidance. Ther Adv Chronic Dis. 2016;7:121–134. doi:10.1177/2040622315627801
   PubMed Web of Science ®Google Scholar
• G. JJ, Akbaral H. Molecular physiology of enteric opioid receptors. Am J Gastroenterol Suppl. 2014;2:17–21. doi:10.1038/ajgsup.2014.5
   PubMedGoogle Scholar
• Yan L, Liu H, Yan R, Tan L, Tan J, Lei Y. Effect of traditional Chinese medicine external therapy for functional constipation: a meta-analysis. Am J Transl Res. 2023;15:13–26.
   PubMed Web of Science ®Google Scholar
• Ziesenitz VC, Vaughns JD, Koch G, Mikus G, van den Anker JN. Pharmacokinetics of fentanyl and its derivatives in children: a comprehensive review. Clin Pharmacokinet. 2018;57:125–149. doi:10.1007/s40262-017-0569-6
   PubMed Web of Science ®Google Scholar
• Paut O, Camboulives J, Viard L, Lemoing JP, Levron JC. Pharmacokinetics of transdermal fentanyl in the peri-operative period in young children. Anaesthesia. 2000;55:1202–1207. doi:10.1046/j.1365-2044.2000.01615-3.x
   PubMed Web of Science ®Google Scholar
• Lynn W, Megan A, Gregory S. Modafinil treatment of opioid-induced sedation. Pain Med. 2010;10:135–140.
   Google Scholar
• Meng SQ, Shi J. Abuse of pharmaceutical drugs and its prevention. Fa Yi Xue Za Zhi. 2021;37:788–795.
   PubMedGoogle Scholar
• Heal DJ, Smith SL, Henningfield JE. CNS stimulants. Neuropharmacology. 2014;87:1–3. doi:10.1016/j.neuropharm.2014.09.025
   PubMed Web of Science ®Google Scholar
• Dackis CA, Gold MS. Addictiveness of central stimulants. Adv Alcohol Subst Abuse. 1990;9:9–26. doi:10.1300/J251v09n01_02
   PubMedGoogle Scholar
• Ibrahim AM, Obaidi Z, Ruan G, Adaramola D, Onguti S. Nalbuphine for opioid-induced urine retention. Ann Intern Med. 2018;169:894–895. doi:10.7326/L18-0387
   PubMed Web of Science ®Google Scholar
• Kim B, Sciascia T, Yosipovitch G. The role of kappa- and mu-opioid receptors in pruritus. SKIN J Cutaneous Med. 2021;5:s31.
   Google Scholar
• Morita T, Tei Y. Skin reaction to both morphine and fentanyl attenuated by steroids and antihistaminics. J Pain Symptom Manage. 2006;32(2):100–101. doi:10.1016/j.jpainsymman.2006.04.002
   PubMed Web of Science ®Google Scholar
• Vertigo professional committee of Chinese medical education association, emergency physician branch of Chinese medical doctor association guidelines for emergency diagnosis and treatment of vertigo (2021). Chin J Emerg Med. 2021;30:402–406.
   Google Scholar
• Sharma V, Simpson SH, Samanani S, Jess E, Eurich DT. Concurrent use of opioids and benzodiazepines/Z-drugs in Alberta, Canada and the risk of hospitalisation and death: a case cross-over study. BMJ Open. 2020;10(11):e038692. doi:10.1136/bmjopen-2020-038692
   PubMed Web of Science ®Google Scholar
• Liu EY, Tamblyn R, Filion KB, Buckeridge DL. Concurrent prescriptions for opioids and benzodiazepines and risk of opioid overdose: protocol for a retrospective cohort study using linked administrative data. BMJ Open. 2021;11(2):e042299. doi:10.1136/bmjopen-2020-042299
   PubMed Web of Science ®Google Scholar
• Ziesenitz VC, Konig SK, Mahlke NS, Skopp G, Haefeli WE, Mikus G. Pharmacokinetic interaction of intravenous fentanyl with ketoconazole. J Clin Pharmacol. 2015;55(6):708–717. doi:10.1002/jcph.469
   PubMed Web of Science ®Google Scholar
• Nozari A, Akeju O, Mirzakhani H, et al. Prolonged therapy with the anticonvulsant carbamazepine leads to increased plasma clearance of fentanyl. J Pharm Pharmacol. 2019;71:982–987. doi:10.1111/jphp.13079
   PubMed Web of Science ®Google Scholar
• Kuip EJ, Zandvliet ML, Koolen SL, Mathijssen RH, van der Rijt CC. A review of factors explaining variability in fentanyl pharmacokinetics; focus on implications for cancer patients. Br J Clin Pharmacol. 2017;83:294–313. doi:10.1111/bcp.13129
   PubMed Web of Science ®Google Scholar
• Geist MJP, Ziesenitz VC, Bardenheuer HJ, Burhenne J, Skopp G, Mikus G. Minor contribution of cytochrome P450 3A activity on fentanyl exposure in palliative care cancer patients. Sci Rep. 2019;9:14635. doi:10.1038/s41598-019-51279-6
   PubMed Web of Science ®Google Scholar
• Baneyx G, Parrott N, Meille C, Iliadis A, Lave T. Physiologically based pharmacokinetic modeling of CYP3A4 induction by rifampicin in human: influence of time between substrate and inducer administration. Eur J Pharm Sci. 2014;56:1–15. doi:10.1016/j.ejps.2014.02.002
   PubMed Web of Science ®Google Scholar
• Kokko H, Hall PD, Afrin LB. Fentanyl-associated syndrome of inappropriate antidiuretic hormone secretion. Pharmacotherapy. 2002;22(9):1188–1192. doi:10.1592/phco.22.13.1188.33526
   PubMed Web of Science ®Google Scholar
• Rastogi R, Swarm RA, Patel TA, Riou B. Case scenario: opioid association with serotonin syndrome: implications to the practitioners. Anesthesiology. 2011;115(6):1291–1298. doi:10.1097/ALN.0b013e31823940c0
   PubMed Web of Science ®Google Scholar
• Kitamura S, Kawano T, Kaminaga S, et al. Effects of fentanyl on serotonin syndrome-like behaviors in rats. J Anesth. 2016;30:178–182. doi:10.1007/s00540-015-2092-y
   PubMed Web of Science ®Google Scholar
• Baldo BA. Opioid analgesic drugs and serotonin toxicity (syndrome): mechanisms, animal models, and links to clinical effects. Arch Toxicol. 2018;92(8):2457–2473. doi:10.1007/s00204-018-2244-6
   PubMed Web of Science ®Google Scholar
• Rickli A, Liakoni E, Hoener MC, Liechti ME. Opioid-induced inhibition of the human 5-HT and noradrenaline transporters in vitro: link to clinical reports of serotonin syndrome. Br J Pharmacol. 2018;175(3):532–543. doi:10.1111/bph.14105
   PubMed Web of Science ®Google Scholar
• Kim JH, Kim M, Sung CW, et al. High-dose fentanyl patch for cancer pain of a patient with cholangiocarcinoma. Korean J Intern Med. 2010;25(3):337–340. doi:10.3904/kjim.2010.25.3.337
   PubMedGoogle Scholar
• Dai YM, Cui TJ, Lin GS. Clinical observation of high-dose fentanyl transdermal patch in the treatment of advanced cancer pain. Mod Tumor Med. 2016;24:138–139.
   Google Scholar
• Pergolizzi J, H. BR, Budd K, et al. Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone). Pain Pract. 2008;8:287–313. doi:10.1111/j.1533-2500.2008.00204.x
   PubMedGoogle Scholar
• Singleton MA, Rosen JI, Fisher DM, Kitamura S, Kawano T, Kaminaga S. Pharmacokinetics of fentanyl in the elderly. Br J Anaesth. 1988;60:178–182. doi:10.1093/bja/60.6.619
   Web of Science ®Google Scholar
• H. SS, Ghosh P, Newman B, et al. On the road to development of an in Vitro Permeation Test (IVPT) model to compare heat effects on transdermal delivery systems: exploratory studies with nicotine and fentanyl. Pharm Res. 2017;34:1817–1830. doi:10.1007/s11095-017-2189-0
   PubMed Web of Science ®Google Scholar
• Chinese nursing society, expert consensus on nursing guidance for cancer pain patients (2017 edition). Chin J Nurs Manag. 2017;17:1585–1586.
   Google Scholar
• Zhang HZ, Yu HY, Wen CD. Application and effect analysis of information-based whole process management in outpatient cancer pain management. Hosp Manag Forum. 2019;272:73–75.
   Google Scholar
• Li WJ, Liu JY, Si Q. The development and change of the concept of cancer pain drug treatment. J Med. 2021;40:45–51.
   Google Scholar